Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen Inc (NASDAQ: AMGN), Revance Therapeutics (NASDAQ: RVNC) and AnaptysBio Inc (NASDAQ: ANAB)

By Ryan Adsit

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen Inc (AMGNResearch Report), Revance Therapeutics (RVNCResearch Report) and AnaptysBio Inc (ANABResearch Report).

Amgen Inc (AMGN)

Cantor Fitzgerald analyst Alethia Young maintained a Hold rating on Amgen Inc today and set a price target of $223. The company’s shares closed yesterday at $199.01.

Young wrote:

“We visited Amgen’s headquarters in conjunction with our post ASH bus tour and met the company’s CFO, R&D head, and IR team. We highlight key takeaways in this note. Management continues to sound very bullish about the Aimovig launch even as competitors launch. We could expect a decision on the Sandoz case around the mediation in Jan. We would expect 2019 guidance range to be as wide or a bit wider than 2018 due to biosimilars. From speaking to management, we think the biggest moving piece is Neulasta experiencing now two biosimilar competitors. When looking at analogs, the company notes drug lost about 50% share, but Amgen has the OnPro device, which may allow it to slow the rate of branded loss. Sensipar ($1.7B ’18 Bloomberg consensus) is a moving piece since generics have not launched at risk.”

According to TipRanks.com, Young is a 4-star analyst with an average return of 5.0% and a 46.8% success rate. Young covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Puma Biotechnology, and Intercept Pharma.

Currently, the analyst consensus on Amgen Inc is a Moderate Buy with an average price target of $207.23, a 4.1% upside from current levels. In a report issued on December 4, Barclays also maintained a Hold rating on the stock with a $195 price target.

.

See today’s analyst top recommended stocks >>

Revance Therapeutics (RVNC)

Mizuho Securities analyst Difei Yang maintained a Buy rating on Revance Therapeutics today and set a price target of $42. The company’s shares closed yesterday at $24.20.

Yang observed:

“We see the deal as attractive and one that could offer additional upside down the road. We believe the most important catalyst for the shares will be the upcoming BLA filing in 1H19 and potentially regular approval thereafter for RT002 in glabellar lines.”

According to TipRanks.com, Yang is a 5-star analyst with an average return of 17.9% and a 46.2% success rate. Yang covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Audentes Therapeutics, and Nektar Therapeutics.

Currently, the analyst consensus on Revance Therapeutics is a Strong Buy with an average price target of $47, a 94.2% upside from current levels. In a report issued on December 4, Cantor Fitzgerald also maintained a Buy rating on the stock with a $50 price target.

.

AnaptysBio Inc (ANAB)

In a report released today, Eliana Merle from Cantor Fitzgerald maintained a Buy rating on AnaptysBio Inc, with a price target of $140. The company’s shares closed yesterday at $71.59, close to its 52-week low of $62.56.

Merle commented:

“. $140 price target. We recently hosted ANAB management in a group meeting with investors. We continue to believe the recent pullback represents an attractive opportunity into major 2H 2019 readouts. We think the lack of near-term catalysts has weighed on shares. However, from our diligence around the two clinical assets (IL-33 and IL-36R inhibitor) and recent management conversations we continue to have conviction into key 2H 2019 datasets, for example, atopic dermatitis ph2b and palmoplantar pustulosis ph2 proof of concept data.”

According to TipRanks.com, Merle is a 1-star analyst with an average return of -5.0% and a 0.0% success rate. Merle covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, BioMarin, and ProQR.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for AnaptysBio Inc with a $137.83 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.